We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

A Phase 3 Study of F14 for Management of Pain Following Total Knee Replacement

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT05603832
Recruitment Status : Recruiting
First Posted : November 3, 2022
Last Update Posted : January 20, 2023
Information provided by (Responsible Party):
Arthritis Innovation Corporation

Brief Summary:
This is a Phase 3, randomized, double blind, multicenter study to evaluate the analgesic efficacy and safety of a single intra-articular dose of F14 (625 mg sustained release celecoxib) administered concurrent with multimodal analgesia in patients undergoing total knee replacement surgery, compared to multimodal analgesia alone.

Condition or disease Intervention/treatment Phase
Post Operative Pain Drug: F14 Drug: 0.25 % Bupivacaine HCl Drug: Acetaminophen Drug: Methocarbamol Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 150 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 3, Multicenter, Randomized, Double-Blind, Parallel Group Study of the Efficacy and Safety of a Single Administration of F14 for Postoperative Analgesia in Patients Undergoing Unilateral Total Knee Replacement
Actual Study Start Date : November 17, 2022
Estimated Primary Completion Date : September 2023
Estimated Study Completion Date : June 2024

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Knee Replacement

Arm Intervention/treatment
Experimental: F14 + Multimodal Analgesia Drug: F14
625 mg intra-articular sustained-release celecoxib

Drug: 0.25 % Bupivacaine HCl
Local anesthetic

Drug: Acetaminophen

Drug: Methocarbamol
Muscle relaxant

Active Comparator: Multimodal Analgesia Drug: 0.25 % Bupivacaine HCl
Local anesthetic

Drug: Acetaminophen

Drug: Methocarbamol
Muscle relaxant

Primary Outcome Measures :
  1. Time-weighted Area Under the Curve (AUC) of numeric rating scale (NRS) pain scores [ Time Frame: 2 weeks ]

Secondary Outcome Measures :
  1. Index knee range of motion (ROM) at 6 weeks [ Time Frame: 6 weeks ]
  2. Time-weighted AUC of NRS pain scores [ Time Frame: 7 Days ]
  3. Time-weighted AUC of NRS pain scores [ Time Frame: 6 weeks ]
  4. Proportion of subjects using opioid rescue medication at 2 weeks [ Time Frame: 2 weeks ]
  5. Time-weighted AUC of NRS pain scores [ Time Frame: 3 days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   45 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male and/or females indicated for primary, unilateral total knee replacement (TKR)
  • Between 45-80 years of age inclusive at the time of signing the informed consent
  • Capable of giving signed informed consent and complying with requirements and restrictions listed in the informed consent form (ICF) and in this protocol
  • Body Mass Index (BMI) ≤ 40 kg/m2
  • Medically stable as determined by the Investigator, based on physical examination, clinical laboratory tests, and 12-lead electrocardiogram (ECG) findings, as well as medical history from patient and pre-study source documents from other care providers
  • Absence of moderate to severe fixed flexion deformity
  • Absence of moderate to severe varus or valgus deformity
  • Minimum pre-operative flexion arc of 100 degrees
  • Absence of steroid, hyaluronic acid, platelet rich plasma, or any other type of therapeutic injection(s) in the index knee within 3 months before scheduled surgery
  • American Society of Anesthesiologists Physical Status Classification System (ASA-PSC) score ≤ 3
  • Females of childbearing potential with a negative serum pregnancy test at screening, or males that have a partner who is a woman of child-bearing potential (WOCBP), who agree to employ adequate birth control measures for the full duration of the study.

Exclusion Criteria:

  • Known allergy or hypersensitivity to active ingredient celecoxib, OR known allergy or hypersensitivity to sulfonamide antibiotics or sulfa containing drugs when an allergy to celecoxib is unknown
  • Unwilling or unable to discontinue use of nonsteroidal anti-inflammatory drugs (NSAIDs) at least 7 days before study surgery and for 6 weeks following study surgery
  • Unwilling or unable to discontinue use of medical or recreational marijuana or cannabidiol (CBD) at least 10 days before study surgery and for 3 months following study surgery
  • Unwilling or unable to discontinue use of pregabalin, gabapentin or other drugs for neuropathic pain at least 7 days prior to study surgery and for 3 months following study surgery
  • Unwilling or unable to discontinue opioid analgesics at least 7 days prior to surgery
  • Has an allergy or contraindication to opioids or NSAIDs or acetaminophen
  • Active or past infection in the index knee
  • Total or partial knee arthroplasty in the contralateral knee < 6 months prior to study surgery
  • Knee surgery (including cruciate ligament, cartilage or osteotomy) other than simple arthroscopy in either knee in the last 12 months (excluding contralateral total or partial knee replacement)
  • Documented osteonecrosis within previous 12 months
  • Prior or current presence of hardware in index knee other than screws from previous ligament repair that do not require manipulation or removal for TKR surgery
  • Other planned major surgery within 12 months of study surgery
  • Concurrent painful physical condition that is unrelated to the study knee (e.g., back, shoulder or contralateral knee pain) that will require analgesic treatment, such as NSAIDs or opioids, during study follow-up
  • Current NRS pain intensity in the contralateral knee with a severity ≥ 4
  • Current or historical evidence of any clinically significant disease or condition, especially cardiovascular, pulmonary or neurological, that, in the opinion of the Investigator, may increase the risk of surgery or complicate or affect the subject's study follow-up
  • Suspected opioid abuse in the last 12 months with a score exceeding 5 on the DAST-10 questionnaire, and/or taking opioids ≥ 46 of the previous 90 days, and currently taking >90 mg in morphine milligram equivalents (MME) at least 5 days per week in the month prior to screening.
  • History of alcohol abuse within previous 12 months (score of 4 on CAGE questionnaire)
  • Anxiety Sensitivity Index (ASI) score >40
  • Fear of Pain Score (FPQ-III) score >120
  • Uncontrolled depression, mood or anxiety disorder (score exceeding 14 on PHQ-9 questionnaire)
  • Participation or scheduled participation in another clinical study involving an investigational drug or device within one calendar month before screening or during study follow-up
  • Current medical diagnosis or patient-reported seizure disorder
  • Current peripheral neuropathy
  • History of complex regional pain syndrome (CRPS)
  • Diagnosis of clinically significant liver and/or renal abnormalities within previous 2 years
  • Diagnosis of diabetes with HbA1c ≥7
  • Current inflammatory arthritides (e.g., rheumatoid arthritis, lupus erythematosus, ankylosing spondylitis, psoriatic arthritis), or traumatic bone injuries within 12 months before scheduled surgery, except for clinically stable/non-active gout that does not affect the knee and does not interfere with walking
  • Treatment with immunosuppressants within one calendar month of intervention. Also, antipsychotics, anticholinergics, or anticonvulsants within one calendar month of intervention unless stable dosage established for > one calendar month and does not plan to change during 3 month follow up
  • Diagnosis of skin disorders including psoriasis, vascular insufficiency ulcers, and chronic venous stasis
  • Subjects with sleep apnea associated with a history of postoperative delirium. If symptomatic sleep apnea is currently treated with continuous positive airway pressure (CPAP) or bilevel positive airway pressure (BIPAP), use must be continued post-operatively
  • History of coronary or vascular stent placed within 3 months
  • Had a malignancy in the last 12 months, except for non-metastatic basal cell or squamous cell carcinoma of the skin or localized carcinoma in situ of the cervix
  • Positive urine drug screen for disallowed medication pre-operatively on day of study surgery
  • Participation in active or pending personal injury or workers' compensation litigation related to index knee
  • Any reason based on investigator clinical judgment, that subject may be non-compliant with respect to study obligations or assessments

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05603832

Layout table for location contacts
Contact: Matthew Shive, PhD 303-269-1213 Matthew.Shive@AIC.com

Layout table for location information
United States, Texas
HD Research - First Surgical Hospital Recruiting
Bellaire, Texas, United States, 77401
Principal Investigator: Solanki         
HD Research - Legent Orthopedic Hospital Recruiting
Carrollton, Texas, United States, 75006
Principal Investigator: Evanson         
Endeavor Clinical Trials Recruiting
San Antonio, Texas, United States, 78240
Principal Investigator: Salazar         
United States, Utah
CenExel JBR Recruiting
Salt Lake City, Utah, United States, 84107
Principal Investigator: Bertoch         
Sponsors and Collaborators
Arthritis Innovation Corporation
Layout table for investigator information
Study Director: Matthew Shive, PhD Arthritis Innovation Corporation
Layout table for additonal information
Responsible Party: Arthritis Innovation Corporation
ClinicalTrials.gov Identifier: NCT05603832    
Other Study ID Numbers: 100-CIP02-P
First Posted: November 3, 2022    Key Record Dates
Last Update Posted: January 20, 2023
Last Verified: January 2023

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Pain, Postoperative
Postoperative Complications
Pathologic Processes
Neurologic Manifestations
Anesthetics, Local
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Analgesics, Non-Narcotic
Muscle Relaxants, Central
Neuromuscular Agents